• Home
  •  / ThermoGenesis

ThermoGenesis

OverviewSuggest Edit

ThermoGenesis Holdings (formerly known as Cesca Therapeutics) is a regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division provides a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. ThermoGenesis’s clinical development division is leveraging its proprietary AutoXpress technology platform to develop stem cell-based therapies in the immuno-oncology, vascular, cardiology and orthopedic markets.

TypePublic
Founded1986
HQRancho Cordova, CA, USMap
Websitethermogenesis.com
Employee Ratings2More

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)53(-38%)
Revenue (FY, 2019)$13 M(+35%)
Share Price (Jan 2021)$2.3 (-3%)
Cybersecurity ratingAMore

Key People/Management at ThermoGenesis

Chris Xu

Chris Xu

Chairman & Chief Executive Officer
Philip Coelho

Philip Coelho

Chief Technology Officer
Debra Donaghy

Debra Donaghy

Director
Haihong Zhu

Haihong Zhu

Chief Operating Officer
Russell Medford

Russell Medford

Director
Jeff Cauble

Jeff Cauble

Chief Financial Officer
Show more

ThermoGenesis Office Locations

ThermoGenesis has offices in Rancho Cordova and Wuxi Shi
Rancho Cordova, CA, US (HQ)
2711 Citrus Rd
Wuxi Shi, CN
800 Jiefang E Rd, Zhong Shan Lu, Liangxi Qu
Show all (2)

ThermoGenesis Financials and Metrics

ThermoGenesis Revenue

Embed Graph
View revenue for all periods
ThermoGenesis's revenue was reported to be $13.05 m in FY, 2019
USD

Revenue (Q2, 2020)

2.2m

Gross profit (Q2, 2020)

(2.6m)

Gross profit margin (Q2, 2020), %

(117.4%)

Net income (Q2, 2020)

(6.5m)

EBIT (Q2, 2020)

(5.2m)

Market capitalization (15-Jan-2021)

18.1m

Closing stock price (15-Jan-2021)

2.3

Cash (30-Jun-2020)

7.0m

EV

12.4m
ThermoGenesis's current market capitalization is $18.1 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

19.0m18.0m16.0m16.0m11.9m6.0m9.7m13.0m

Revenue growth, %

0%(26%)

Cost of goods sold

12.7m11.6m10.1m11.3m9.2m3.9m7.5m7.4m

Gross profit

6.3m6.4m5.9m4.7m2.7m2.2m2.2m5.7m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

4.9m4.8m4.9m4.1m4.8m4.9m3.6m4.5m4.0m3.7m4.6m4.0m2.8m3.3m2.8m3.8m4.0m3.3m3.1m1.9m2.0m3.1m3.0m4.3m4.1m3.2m2.2m

Cost of goods sold

2.9m3.1m3.7m2.5m2.8m3.2m2.3m2.7m2.5m2.5m3.1m2.9m2.5m2.3m2.4m2.4m2.5m1.9m9.9m1.5m1.6m2.5m1.7m2.4m2.2m1.7m4.9m

Gross profit

2.0m1.7m1.2m1.6m2.0m1.7m1.4m1.8m1.5m1.2m1.5m1.1m367.0k1.0m408.0k1.4m1.6m1.4m(6.8m)352.0k363.0k655.0k1.3m2.0m1.9m1.5m(2.6m)

Gross profit Margin, %

41%36%24%39%41%34%38%40%38%32%33%28%13%31%14%37%39%42%(221%)19%18%21%42%45%47%47%(117%)
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

7.9m6.9m14.8m3.4m5.8m3.5m2.4m3.2m

Accounts Receivable

4.6m4.9m4.7m5.1m1.7m1.5m1.3m

Prepaid Expenses

338.0k232.0k217.0k163.0k594.0k224.0k602.0k

Inventories

6.3m4.3m5.6m4.6m4.8m4.5m3.8m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

10.8m8.7m8.5m8.8m7.5m7.5m5.3m2.3m6.6m10.7m8.4m4.8m6.6m2.9m7.2m5.6m4.9m3.8m2.5m2.9m3.1m2.2m2.2m2.4m2.8m5.7m7.0m

Accounts Receivable

4.4m5.0m4.8m3.5m5.4m4.9m4.2m5.5m5.6m4.4m4.6m5.7m3.6m3.5m4.0m3.0m3.0m3.0m258.0k1.5m2.1m2.0m3.1m4.5m2.0m1.7m

Prepaid Expenses

315.0k170.0k111.0k366.0k420.0k338.0k319.0k136.0k198.0k490.0k300.0k200.0k131.0k336.0k262.0k203.0k260.0k334.0k557.0k286.0k313.0k389.0k451.0k429.0k837.0k

Inventories

6.6m6.8m6.4m6.2m5.4m4.3m4.4m4.2m4.8m5.9m5.2m5.0m4.0m4.0m3.5m3.4m2.8m3.5m282.0k5.2m4.3m4.3m4.0m3.4m4.2m5.2m
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(5.0m)(3.1m)(8.6m)(14.9m)(18.6m)(2.8m)(40.9m)(10.1m)

Depreciation and Amortization

604.0k538.0k993.0k1.4m1.2m322.0k670.0k805.0k

Inventories

120.0k795.0k(1.3m)416.0k375.0k(367.0k)61.0k610.0k

Accounts Payable

696.0k619.0k(295.0k)1.4m(2.4m)469.0k214.0k(966.0k)
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(1.2m)(2.5m)(4.2m)995.0k432.0k(689.0k)(2.3m)(3.9m)(5.8m)(3.3m)(7.7m)(12.5m)(3.4m)(4.0m)(14.9m)(22.4m)(25.8m)(27.9m)(3.4m)(30.5m)(33.6m)(2.0m)(3.5m)(5.9m)(4.7m)(11.3m)

Depreciation and Amortization

99.0k202.0k388.0k134.0k266.0k400.0k156.0k327.0k587.0k322.0k667.0k1.0m365.0k659.0k876.0k261.0k473.0k660.0k159.0k333.0k506.0k212.0k402.0k604.0k199.0k392.0k

Inventories

230.0k(322.0k)20.0k13.0k710.0k994.0k(162.0k)7.0k(430.0k)(332.0k)157.0k66.0k594.0k568.0k568.0k258.0k811.0k599.0k(224.0k)(358.0k)336.0k99.0k449.0k980.0k(400.0k)(5.1m)

Accounts Payable

29.0k(143.0k)131.0k(982.0k)(1.1m)(1.1m)112.0k(369.0k)(397.0k)(571.0k)(404.0k)1.1m300.0k(626.0k)(1.7m)(832.0k)(587.0k)(738.0k)69.0k(242.0k)(407.0k)38.0k749.0k(542.0k)1.0m1.8m
show all
USDQ1, 2012

Financial Leverage

1.2 x
Show all financial metrics

ThermoGenesis Operating Metrics

FY, 2016

Patents Issued

25
Show all operating metrics

ThermoGenesis Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

Learn more about our premium products
SecurityScorecard logo

ThermoGenesis Online and Social Media Presence

ThermoGenesis's Trends

Embed Graph

ThermoGenesis News and Updates

December 21, 2020

Outlook on the Biopreservation Global Market to 2026 - Profiling Avantor, BioLife Solutions and ThermoGenesis Among Others

Dublin, Dec. 21, 2020 (GLOBE NEWSWIRE) -- The "Biopreservation Market by Type, Application, End-user, and Geography - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. Biopreservation is a process that assists in the conservation of biospecimens such as DNA, sa…
September 02, 2020

ThermoGenesis Unveils Comprehensive Suite of Products and Services to Fight the Global COVID-19 Pandemic

RANCHO CORDOVA, Calif., Sept 2, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, along with its joint venture, ImmuneCyte, Inc. today announced plans to roll out a...
August 31, 2020

ThermoGenesis Holdings to Participate in Investor Conferences in September

RANCHO CORDOVA, Calif., Aug. 31, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced management's participation in the following investor conferences in...
March 27, 2020

ThermoGenesis Holdings Announces Closing Of $3.5 Million Registered Direct Offering Priced At-the-Market

RANCHO CORDOVA, Calif., March 27, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that it closed its previously announced registered direct offering for...
October 31, 2019

Cesca Therapeutics To Change Name And Ticker Symbol To Reflect New Strategic Focus

RANCHO CORDOVA, Calif., Oct. 31, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing for regenerative medicine, today announced that the company will change its name to ThermoGenesis Holdings, Inc. ("ThermoGenesis") in order to better...
October 22, 2019

Cesca Therapeutics Forms Joint Venture with Healthbanks Biotech (USA) to Provide Immune Cell Banking and Cell Processing Services

RANCHO CORDOVA, Calif., Oct. 22, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary, today announced that the company has...
Show more

ThermoGenesis Blogs

January 02, 2020

ThermoGenesis Holdings Announces Board of Directors and Management Changes

RANCHO CORDOVA, Calif., Jan. 2, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that, effective December 31, 2019, Debra Donaghy, CPA, CMA, CTP, has been appointed to its Board of …
December 11, 2019

LD Micro 12th Annual Main Event

Disclosure and Forward Looking Statement — This presentation includes statements of future expectations and other forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current …
December 10, 2019

ThermoGenesis Holdings Updates 510(K) Listing with the FDA to Include its Next Generation PXP®-1000 System for Advanced Cellular Processing

RANCHO CORDOVA, Calif., Dec. 10, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that it has completed the development process and submitted a Letter to the Design History File and…
December 05, 2019

ThermoGenesis Holdings to Present at the LD Micro 12th Annual Main Event

RANCHO CORDOVA, Calif., Dec. 5, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced Chris Xu, Ph.D., Chairman and Chief Executive Officer, will present a company overview at the LD Micr…
November 26, 2019

ThermoGenesis Holdings Closes Joint Venture Agreement With HealthBanks Biotech (USA) to Form ImmuneCyte Life Sciences

ImmuneCyte to Begin Operations by Year End 2019   RANCHO CORDOVA, Calif., Nov. 26, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the company has closed on its joint venture …
November 19, 2019

ThermoGenesis Holdings Announces Improved Third Quarter 2019 Financial Results and Provides Corporate Update

Reports Second Consecutive Quarter of Positive Cash Flow; Recent Name Change Aligns with Shift in Strategic Focus   Conference Call to be Held Today at 1:30 p.m. PST/4:30 p.m. EST   RANCHO CORDOVA, Calif., November 19, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), formerly known as Cesca Thera…
Show more

 ThermoGenesis Frequently Asked Questions

  • When was ThermoGenesis founded?

    ThermoGenesis was founded in 1986.

  • Who are ThermoGenesis key executives?

    ThermoGenesis's key executives are Chris Xu, Philip Coelho and Debra Donaghy.

  • How many employees does ThermoGenesis have?

    ThermoGenesis has 53 employees.

  • What is ThermoGenesis revenue?

    Latest ThermoGenesis annual revenue is $13 m.

  • What is ThermoGenesis revenue per employee?

    Latest ThermoGenesis revenue per employee is $246.2 k.

  • Who are ThermoGenesis competitors?

    Competitors of ThermoGenesis include Neuronasal, Balmes Transplantation and Rigvir.

  • Where is ThermoGenesis headquarters?

    ThermoGenesis headquarters is located at 2711 Citrus Rd, Rancho Cordova.

  • Where are ThermoGenesis offices?

    ThermoGenesis has offices in Rancho Cordova and Wuxi Shi.

  • How many offices does ThermoGenesis have?

    ThermoGenesis has 2 offices.